StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly (LLY) sleep apnea study data seen as a win, stock gains
April 17, 2024 11:12 AM
Eli Lilly & Co. (NYSE: LLY) announced positive topline results from its SURMOUNT-OSA Ph3 study on Wednesday, which evaluated tirzepatide ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot List
Next Articles
Midday movers: Travelers, JB Hunt fall; United Airlines rises
April 17, 2024 8:09 AM
Inspire Medical (INSP), ResMed (RMD) on Watch Following Report on Sleep Apnea
April 17, 2024 7:09 AM
Eli Lilly & Co. (LLY) reports Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
April 17, 2024 6:15 AM
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
April 17, 2024 6:15 AM
Form 4 ELI LILLY & Co For: Apr 15 Filed by: Sulzberger Gabrielle
April 16, 2024 4:15 PM
Form 4 ELI LILLY & Co For: Apr 15 Filed by: LUCIANO JUAN R
April 16, 2024 4:14 PM
Form 4 ELI LILLY & Co For: Apr 15 Filed by: JOHNSON KIMBERLY H
April 16, 2024 4:13 PM
Form 4 ELI LILLY & Co For: Apr 15 Filed by: Hedley Mary Lynne
April 16, 2024 4:12 PM
Form 4 ELI LILLY & Co For: Apr 15 Filed by: Alvarez Ralph
April 16, 2024 4:11 PM
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
April 16, 2024 10:00 AM
